Suppr超能文献

耐药性泌乳素分泌性垂体腺瘤演变为垂体癌:一例挑战性病例报告及文献复习。

Evolution of a refractory prolactin-secreting pituitary adenoma into a pituitary carcinoma: report of a challenging case and literature review.

机构信息

Department of Neurosurgery, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100730, China.

出版信息

BMC Endocr Disord. 2021 Oct 29;21(1):217. doi: 10.1186/s12902-021-00874-8.

Abstract

BACKGROUND

Pituitary carcinomas (PCs), defined as distant metastases of pituitary neoplasms, are very rare malignancies. Because the clinical presentation of PCs is variable, early diagnosis and management remain challenging. PCs are always refractory to comprehensive treatments, and patients with PCs have extremely poor prognoses.

CASE PRESENTATION

We describe one case of a prolactin-secreting pituitary adenoma (PA) refractory to conventional therapy that evolved into a PC with intraspinal metastasis. A 34-year-old female was diagnosed with an invasive prolactin-secreting PA in 2009 and was unresponsive to medical treatment with bromocriptine. The tumor was gross totally removed via transsphenoidal surgery (TSS). However, the patient experienced multiple tumor recurrences or regrowth despite comprehensive treatments, including medical therapy, two gamma knife radiosurgeries (GKSs), and four frontal craniotomies. In 2016, she was found to have an intradural extramedullary mass at the level of the fourth lumbar vertebra. The intraspinal lesion was completely resected and was confirmed as a metastatic PC based on histomorphology and immunohistochemical staining. The literature on the diagnosis, molecular pathogenesis, treatment, and prognosis of patients with prolactin-secreting PCs was reviewed.

CONCLUSION

PCs are very rare neoplasms with variable clinical features and poor prognosis. Most PCs usually arise from aggressive PAs refractory to conventional therapy. There is no reliable marker to identify aggressive PAs with a risk for progression to PCs; thus, it is difficult to diagnose these PCs early until the presence of metastatic lesions. It is still very challenging to manage patients with PCs due to a lack of standardized protocols for diagnosis and treatment. Establishing molecular biomarkers and the pathobiology of PCs could help in the early identification of aggressive PAs most likely to evolve into PCs.

摘要

背景

垂体癌(PC)定义为垂体肿瘤的远处转移,是一种非常罕见的恶性肿瘤。由于 PC 的临床表现多种多样,早期诊断和管理仍然具有挑战性。PC 对综合治疗总是有抵抗力,并且 PC 患者的预后极差。

病例介绍

我们描述了一例对常规治疗有抗药性的泌乳素分泌性垂体腺瘤(PA)发展为伴有脊髓转移的 PC 的病例。一名 34 岁女性于 2009 年被诊断为侵袭性泌乳素分泌性 PA,对溴隐亭药物治疗无反应。肿瘤通过经蝶窦手术(TSS)进行了大体全切除。然而,尽管进行了包括药物治疗、两次伽玛刀放射外科手术(GKS)和四次额骨开颅术在内的综合治疗,该患者仍经历了多次肿瘤复发或生长。2016 年,她被发现第四腰椎水平有硬脊膜外髓内肿块。脊髓内病变完全切除,并根据组织形态学和免疫组织化学染色结果被确认为转移性 PC。我们对泌乳素分泌性 PC 患者的诊断、分子发病机制、治疗和预后的文献进行了回顾。

结论

PC 是一种非常罕见的肿瘤,具有多变的临床特征和不良的预后。大多数 PC 通常起源于对常规治疗有抗药性的侵袭性 PA。目前尚无可靠的标志物来识别具有向 PC 进展风险的侵袭性 PA,因此,直到出现转移病灶,很难早期诊断这些 PC。由于缺乏诊断和治疗的标准化方案,管理 PC 患者仍然具有很大的挑战性。建立 PC 的分子标志物和病理生物学特性可能有助于早期识别最有可能发展为 PC 的侵袭性 PA。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9454/8555299/6281fadce110/12902_2021_874_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验